IQVIA Holdings (FRA:QTS) Research & Development: €0 Mil (TTM As of Mar. 2026)


FRA:QTS IQVIA Holdings Inc FRA:QTS
88 GF Score
Price €164.25
GF Value €219.41
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is IQVIA Holdings Research & Development?

IQVIA Holdings FRA:QTS -0.09% 88 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates FRA:QTS with a GF Score™ of 88/100 and a GF Value™ of €219.41 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. IQVIA Holdings's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

IQVIA Holdings  (FRA:QTS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

IQVIA Holdings Research & Development Related Terms

IQVIA Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for IQVIA Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings Research & Development Chart

IQVIA Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IQVIA Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:QTS
88GF Score
IQVIA Holdings Inc FRA:QTS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IQVIA Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
IQVIA Holdings (FRA:QTS) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on IQVIA Holdings and its competitors.
Is IQVIA Holdings' Research & Development too high?
IQVIA Holdings' current Research & Development is €0 Mil. Overall, IQVIA Holdings has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IQVIA Holdings' Research & Development compare to NTRA and ILMN?
IQVIA Holdings' Research & Development of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on IQVIA Holdings and its competitors. IQVIA Holdings's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IQVIA Holdings stock overvalued right now?
Based on GuruFocus' analysis, IQVIA Holdings (FRA:QTS) is currently considered Modestly Undervalued. The stock's GF Value™ is €219.41, compared to a current price of €164.25 — trading 25.1% below its estimated fair value. The current Research & Development is €0 Mil. IQVIA Holdings' overall GF Score™ is 88/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For IQVIA Holdings (FRA:QTS), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IQVIA Holdings (FRA:QTS) Overvalued in 2026?

Based on GuruFocus' analysis, IQVIA Holdings stock appears to be undervalued. The current stock price of €164.25 is trading 25.1% below its estimated GF Value™ of €219.41. GuruFocus considers IQVIA Holdings to be Modestly Undervalued.

Key valuation signals for FRA:QTS:

  • Research & Development: €0 Mil
  • GF Value™: €219.41 vs. price of €164.25 (25.1% below fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the FRA:QTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IQVIA Holdings Business Description

Address 2400 Ellis Road, Durham, NC, USA, 27703
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
88GF Score

Get the complete analysis for FRA:QTS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€164.25
Price
€219.41
GF Value